Ability Pharma, a CataloniaBio & HealthTech member focused on the development of innovative oral anticancer compounds, has received a €1.6 million grant from the Food and Drug Administration (FDA).
This year the biopharmaceutical company based at the UAB Research Park expects to raise a total of €9.2 million to fund clinical phase IIb of the ABTL0812 treatment for pancreatic cancer. ABTL0812 has obtained positive results in clinical trial in patients with endometrial and lung cancer.
Last March, Ability received €5 million from the European Innovation Council (EIC). The remaining €2.6 million will come through the collective investment campaign launched this week on the Capital Cell platform and an agreement with an industrial partner.
Photo: Carles Domènech, executive president and CSO of Ability - © Ability Pharma.
You may also be interested in:
Comments